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ABSTRACT
Previous studies have found that tumor-associated macrophages (TAMs) promote 
cancer progression. We previously reported that TAMs promote prostate cancer 
metastasis via activation of the CCL2–CCR2 axis. The CCR4 (receptor of CCL17 and 
CCL22) expression level in breast cancer was reported to be associated with lung 
metastasis. The aim of this study was to elucidate the role of CCR2 and CCR4 in 
prostate cancer progression. CCR2 and CCR4 were expressed in human prostate cancer 
cell lines and prostate cancer tissues. In vitro co-culture of prostate cancer cells and 
macrophages resulted in increased CCL2 and CCR2 levels in prostate cancer cells. 
The addition of CCL2 induced CCL22 and CCR4 production in prostate cancer cells. 
The migration and invasion of prostate cancer cells via enhanced phosphorylation 
of Akt were promoted by CCL17 and CCL22. CCR4 may be a potential candidate for 
molecular-targeted therapy.
INTRODUCTION
Prostate cancer represents one of the most frequently 
diagnosed malignancies in men worldwide [1]. Most 
patients progress to castration-resistant prostate cancer 
after several years of androgen-deprivation therapy, and no 
curative therapies are currently available for this condition 
[2–4]. Within a tumor microenvironment, chemokines 
and their receptors are key players in proliferation and 
metastasis [5, 6]. For instance, CCL2 has been reported 
to be present in the microenvironment of many types 
of cancers, and CCR2 has been demonstrated to be 
upregulated in cancer cells, including prostate cancer 
cells [7]. We previously reported that tumor-associated 
macrophages (TAMs) promote prostate cancer metastasis 
via activation of the CCL2–CCR2 axis [8, 9]. In addition, 
it has been reported that several chemokines are related to 
prostate cancer progression [10–12]. CCL17 and CCL22, 
which are high-affinity ligands of CCR4, have been 
reported to be secreted by TAMs (M2-type macrophages) 
and having immunosuppressive functions [13, 14]. 
Recently, the CCR4 expression level in breast cancer 
was reported to be associated with lung metastasis [15]. 
However, the role of CCR4 and the relationship between 
CCR2 and CCR4 in prostate cancer remains unknown.
Herein, we report that TAMs promote prostate 
cancer progression through the activation of the CCL2–
CCR2 axis, followed by the activation of the CCL17/
CCL22–CCR4 axis. In vitro co-culture of monocyte-
lineage cells with prostate cancer cells induce higher 
expression of CCL2, which promotes the expressions 
of CCR2 and CCR4 in prostate cancer cells. Our results 
suggest that CCR2 and CCR4 play a critical role in 
prostate cancer progression.
RESULTS
Macrophages increased prostate cancer cell 
migration and invasion
U937 cells were used as a model for monocyte-
macrophage differentiation because they share many 
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properties with native monocyte-derived macrophages. 
When floating U937 cells were treated with phorbol 
12-myristate 13-acetate (PMA), the cells stopped 
proliferating, attached to the surface of the plate, and 
differentiated into macrophages (hereafter termed 
U937-M) 24 h later. The U937-M cells expressed CCR7, 
which is an M1-type macrophage marker, but not CD206, 
which is an M2-type macrophage marker, indicating that 
U937-M took on M1-type characteristics. After treatment 
with a conditioned medium (CM) of prostate cancer cells, 
the U937-M cells expressed CD206, which indicated that 
the prostate cancer cells could skew macrophages from 
M1- to M2-type cells, which are almost synonymous with 
TAMs (Figure 1A). The PC-3, DU145, and LNCaP cells 
showed significant increases in transwell migration and 
invasion in response to CM of U937 and U937-M cells 
(Figures 1B, 1C, and Supplementary Figure S1).
Macrophages and prostate cancer cells secreted 
more CCL2 during co-culture
A human cytokine antibody array of CM of PC-3 
cells, PC-3 cells treated with CCL2, and PC-3 cells co-
cultured with THP-1 and U937 cells showed that co-
Figure 1: Co-culture of macrophages and prostate cancer cells increases prostate cancer cell migration and invasion 
and induces CCL2 secretion. A. U937 differentiation to M2 macrophages is determined using western blot analysis. CCR7 (an M1-
type macrophage marker) and CD206 (an M2-type macrophage marker) are assayed using proteins extracted from U937 cells treated with 
PMA for 24 h and exposed to CM of prostate cancer cells. B. Prostate cancer cells are placed in transwell inserts, and CM of U937 and 
U937-M cells is added. C. Prostate cancer cells are placed in transwell inserts with Matrigel®-coated membranes in the upper compartment, 
and U937-M cells are placed in the lower compartments. After 24-h incubation, the cells that had migrated through the membrane are 
stained. The mean optical density (OD) value is read using a microreader at 595 nm. Data are presented as mean ± SD. D. Chemokine 
arrays comparing the CM of PC-3 cells in monoculture and the CM of PC-3 cells co-cultured with monocyte cells. E. Prostate cancer cells 
are co-cultured with U937 cells for 24 h, CM is collected, and CCL2 levels are analyzed using ELISA. Adjustments of brightness, contrast, 
and size are applied to the whole images of western blot-based analyses without elimination of any information present in the original, 
including backgrounds. The mean OD value is read using a microreader at 450 nm, and data are presented as mean ± SD. All experiments 
are performed in triplicate, and the mean values are shown. *p < 0.05, **p < 0.01, ***p < 0.001.
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culturing with U937 cells induced CCL2 secretion and 
did not induce any other cytokines (Figure 1D). Enzyme-
linked immunosorbent assay (ELISA) confirmed that 
CCL2 secretion was dramatically increased when prostate 
cancer cells and U937 cells were co-cultured (Figure 1E).
CCL2 increased migration of prostate 
cancer cells
When prostate cancer cells were treated with human 
recombinant CCL2, migration was induced in a dose-
dependent manner (Figure 2A). As expected, migration 
of U937 cells was also increased by CCL2 treatment 
(Supplementary Figure S2). CCL22 and CCL17 were M2-
type macrophage markers, and U937-M cells took on the 
characteristics of M2-type macrophages after co-culture 
with prostate cancer cells. Therefore, the levels of CCL22 
and CCL17 in the co-cultured media of DU145 cells and 
THP-1 or U937 cells were measured. The CCL22 levels 
were increased in co-cultured media, but the CCL17 level 
was very low and could hardly be measured (Figure 2B). 
Because this finding indicated that CCL2 secretion after 
co-culture induced CCL22, CCL2 was directly added to 
DU145 cells and CCL22 was measured. As expected, 
Figure 2: CCL2 promotes prostate cancer cell migration and induces CCL22 secretion, which is a ligand of CCR4. A. 
Prostate cancer cells are placed in transwell inserts and treated with CCL2 (0–30 ng/ml). After 24-h incubation, PC-3 and DU145 cells that 
had migrated through the membrane are stained. The mean OD value is read using a microreader at 595 nm. Migration of LNCaP cells is 
assessed with a wound-healing assay. Data are presented as mean ± SD. B. DU145 cells are co-cultured with THP-1 and U937 cells and 
treated with CCL2 (30 ng/ml) for 24 h, CM is collected, and CCL17 and CCL22 levels are analyzed using ELISA. The mean OD value is 
read using a microreader at 450 nm, and data are presented as mean ± SD. C, D. Total RNA and protein are extracted from prostate cancer 
cells, and CCR2 and CCR4 gene and protein expression levels are analyzed using PCR (C) and western blot (D). E. Prostate cancer cells 
(1.0 × 105 cells/well) are seeded into 6-well plates and cultured until they reach 60%–70% confluence. Cells are incubated with anti-CCR2 
or anti-CCR4 antibody and detected using a second antibody conjugated with FITC (green). Cells are counterstained with 4',6-diamidino-
2-phenylindole (blue). Adjustments of brightness, contrast, and size are applied to the whole images of western blot-based analyses without 
elimination of any information present in the original, including backgrounds. All experiments are performed in triplicate, and mean values 
are shown. *p < 0.05, **p < 0.01, ***p < 0.001.
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CCL2 induced CCL22 secretion from DU145 cells 
(Figure 2B).
Both CCR2 and CCR4 were expressed in 
prostate cancer cells
Because CCL2 is a high-affinity ligand for CCR2, 
CCL2 was thought to increase cell migration through 
CCR2 receptors. We hypothesized that prostate cancer 
cells also utilize the CCL2–CCR2 axis and the subsequent 
CCL17/CCL22–CCR4 axis to metastasize. We first 
examined CCR2 and CCR4 mRNA expressions in human 
prostate cancer cells. Quantitative reverse transcription 
polymerase chain reaction (RT-PCR) showed that CCR2 
and CCR4 were expressed in all prostate cancer cell lines 
that we checked (Figure 2C). Further analyses of protein 
levels, including western blot and immunocytochemical 
staining, showed that CCR2 and CCR4 were expressed in 
all prostate cancer cell lines (Figures 2D and 2E).
CCL2 increased not only CCL22 but also CCR2 
and CCR4
Previously, it has been reported that co-culture of 
prostate cancer cells and macrophages increased CCR2 and 
CCL2 expression levels [8]. To determine whether CCL2 
contributes to upregulation of CCR2 in prostate cancer 
cells, PC-3, DU145, and LNCaP cells were treated with 
CCL2. Stimulation of prostate cancer cells with CCL2 was 
found to induce CCR2 production (Figure 3A). Moreover, 
CCL2, CCL17, and CCL22 stimulation induced CCR4 
production (Figure 3B). Consistently, co-culture with U937 
Figure 3: CCL2 increases not only CCL22 but also CCR2 and CCR4. A. Prostate cancer cells are treated with CCL2 (30 ng/
ml) for 24 h, and western blot for CCR2 is performed. B. Prostate cancer cells are treated with CCL2, CCL17, and CCL22 (30 ng/ml) for 
24 h, and western blot for CCR4 is performed. C. Prostate cancer cells are co-cultured with U937 or U937-M cells for 24 h, and western 
blot for CCR4 is performed. D. Prostate cancer cells are placed in transwell inserts and treated with CCL17 and CCL22 (0–30 ng/ml). After 
24-h incubation, PC-3 and DU145 cells that had migrated through the membrane are stained. The mean optical density (OD) value is read 
using a microreader at 595 nm. Migration of LNCaP cells is assessed with a wound-healing assay. Adjustments of brightness, contrast, and 
size are applied to the whole images of western blot-based analyses without elimination of any information present in the original, including 
backgrounds. Data are presented as mean ± SD. All experiments are performed in triplicate, and mean values are shown. *p < 0.05, **p < 
0.01, ***p < 0.001.
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and U937-M cells also induced CCR4 production, and the 
CCR4 production was greater with U937-M cells than with 
U937 cells (Figure 3C). These results indicated that there is 
crosstalk between prostate cancer cells and macrophages, 
and that the CCL2 signal is amplified by CCL22 secretion 
and upregulation of their receptors.
Next, the effects of CCL17 and CCL22 on prostate 
cancer cells were analyzed using a transwell migration 
assay and a wound-healing assay. PC-3 and DU145 
cells showed significant increases in migration ability in 
response to CCL17 and CCL22 treatments (Figure 3D). In 
the wound-healing assay, CCL17 and CCL22 treatments 
also significantly enhanced the migration of LNCaP cells 
(Figure 3D).
Blockade of the CCL2–CCR2 or CCL17/22–
CCR4 axis inhibited the migration of prostate 
cancer cells
To confirm that the CCL2–CCR2 axis and its 
downstream CCL17/22–CCR4 axis really contributed to the 
induction of prostate cancer cell migration, the CCL2–CCR2 
or CCL17/22–CCR4 axis was blocked using a receptor 
antagonist. CCR2 and CCR4 antagonists clearly inhibited the 
migration ability of prostate cancer cells, which was induced 
by CCL2 and CCL17/CCL22 (Figure 4). Interestingly, a 
CCR4 antagonist could inhibit the migration ability induced 
by CCL2 (Supplementary Figure S3A). Moreover, a CCR2 
antagonist also inhibited the migration ability of prostate 
cancer cells induced by U937 and U937-M cells (Figure 4). 
As expected, increased migration of U937 cells caused by 
CCL2 treatment was also inhibited by the CCR2 antagonist 
(Supplementary Figure S3B). These results showed that 
CCR2 and CCR4 expressed by the prostate cancer cells 
were sufficient to cause migration when treated with CCL2, 
CCL17, and CCL22, or CM collected from U937 cells and 
M2-type macrophages U937-M cells.
CCR2 and CCR4 were expressed more strongly 
in prostate cancer tissue than in normal prostate 
tissue
To determine CCR2 and CCR4 receptor expressions 
in human prostate cancer tissue, immunohistochemical 
Figure 4: Blockade of the CCL2–CCR2 or CCL17/22–CCR4 axis inhibits the migration of prostate cancer cells. Prostate 
cancer cells are incubated with a CCR2 antagonist (CCR2 ant; 20 μg/ml) or CCR4 antagonist (CCR4 ant; 10 μg/ml) for 30 min and then 
incubated with CCL2 (10–30 ng/ml), CCL17 (10–30 ng/ml), CCL22 (10–30 ng/ml), or CM of U937 or U937-M cells for 24 h for PC-3 and 
DU145 and 48 h for LNCaP. The mean optical density (OD) value is read using a microreader at 595 nm. Data are presented as mean ± SD. 
All experiments are performed in triplicate, and mean values are shown. *p < 0.05, **p < 0.01, ***p < 0.001.
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(IHC) staining was performed using a pair of the same 
tissue microarray (TMA) plates. The backgrounds of 
the patients are shown in Supplementary Table S1. IHC 
analysis revealed a significant increase in both CCR2 
and CCR4 expressions in prostate cancer cells compared 
with the expressions in epithelial cells in normal prostate 
tissues (Figures 5A and 5B). Interestingly, the staining 
intensities of CCR2 and CCR4 in each specimen were 
significantly correlated (Supplementary Figure S4A). 
When the staining intensities of tissues were averaged 
in every patient, the staining intensities of CCR2 and 
CCR4 still showed significant correlations (Figure 5C). 
The staining intensity of CCR2 was not correlated with 
the progression of TNM stage (Supplementary Figure 
S4B), whereas that of CCR4 was correlated (Figure 5D). 
The staining intensities of CCR2 and CCR4 were not 
correlated with the Gleason score (Supplementary Figures 
S4C and S4D). These results from clinical samples support 
our in vitro data showing that the CCL2–CCR2 axis-
induced CCL22 triggered CCR4 production and that both 
the CCL2–CCR2 and CCL22–CCR4 axes contributed to 
prostate cancer progression.
Figure 5: CCR4 and CCR2 are increased in prostate cancer tissues on IHC staining. A, B. A TMA plate containing tissue 
samples from 8 patients with normal prostates and tissue samples from 36 patients with prostate cancer is used, and one or two spotted 
tissues from each patient are placed on the plate. IHC staining of CCR2 (A) and CCR4 (B) is performed and scored on a scale from – to 
+++, according to intensity. Patients having two spotted tissues are scored using the average value. C. Correlation between the staining 
intensities of CCR2 and CCR4 in each patient is analyzed using Pearson’s correlation coefficient test. D. The CCR4 staining intensity is 
analyzed according to the progression of TNM stage. One-way ANOVA is performed. Bars indicate the mean of each group.
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Activation of Akt is a critical step downstream 
of the CCL22–CCR4 axis for prostate cancer 
migration
To verify that CCR2 and CCR4 are functional in 
prostate cancer cells, the effects of CCL2, CCL17, and 
CCL22 on the activation of Akt signaling pathways 
were tested. Rapid phosphorylation of Akt (Ser473) was 
observed at 30 min after CCL2, CCL17, and CCL22 
treatment (Figure 6A), but not Thr308 (Supplementary 
Figure S5). A CCR4 antagonist strongly inhibited 
chemokine-induced phosphorylation of Akt (Ser473) 
(Figure 6A), and a CCR2 antagonist strongly inhibited 
CCL2-induced phosphorylation of Akt (Ser473) 
(Supplementary Figure S6). U937 cell-induced 
phosphorylation of Akt (Ser473) was also inhibited by 
Figure 6: The CCL2–CCR2 and CCL22–CCR4 axes increase phosphorylation of Akt. A. Phosphorylation of Akt (Ser473) 
proteins in prostate cancer cells is assayed using western blot at 30 min after CCL2, CCL17, or CCL22 stimulation (left panels) and 
after CCR4 antagonist treatment with CCL2, CCL17, or CCL22 stimulation (right panels). B. U937 cell-induced phosphorylation of Akt 
(Ser473) proteins in prostate cancer cells with or without CCR2 and CCR4 antagonists is also assayed using western blot. Adjustments of 
brightness, contrast, and size are applied to the whole images of western blot-based analyses without elimination of any information present 
in the original, including backgrounds. C. PC-3 cells are incubated with the Akt inhibitor AZD5363 (10 μg/ml) with CCL17 (30 ng/ml) 
and CCL22 (30 ng/ml) for 24 h. The mean optical density (OD) value is read using a microreader at 595 nm. Data are presented as mean ± 
SD. All experiments are performed in triplicate, and mean values are shown. **p < 0.01. All experiments are performed in triplicate, and 
representative data are shown.
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the CCR2 and CCR4 antagonists (Figure 6B). Because 
the phosphorylation of Akt (Ser473) was more strongly 
inhibited by the CCR4 antagonist than by the CCR2 
antagonist, CCR4 may contribute more to prostate 
cancer cell migration than CCR2 (Figure 6B). Moreover, 
AZD5363, a potent inhibitor of Akt, inhibited CCL17- and 
CCL22-induced prostate cancer migration (Figure 6C). 
These findings showed that TAMs phosphorylated Akt 
and induced prostate cancer cell migration and invasion 
via activation of the CCL22–CCR4 axis.
DISCUSSION
It has been established that the majority of 
malignant tumors contain numerous macrophages as 
major components of the host leukocytic infiltrate 
[16]. Macrophage recruitment is mediated by a variety 
of chemoattractants, and macrophages in tumor 
microenvironments are defined as TAMs and exhibit an 
M2-type characteristic [17]. It has been shown that CCL2 
plays an important role in macrophage accumulation at 
the tumor site through evidence indicating that tumor-
derived CCL2 levels were correlated with the abundance 
of TAMs in several types of cancers [18–21]. TAMs have 
been reported to secrete M2-type macrophage markers, 
including both CCL17 and CCL22; therefore, our study 
focused on the CCL17/CCL22–CCR4 axis with regard 
to interactions between TAMs and prostate cancer cells. 
However, to our knowledge, the expression and role of 
CCR4 in prostate cancer have not been reported so far, 
and little is known about the relationship between TAMs 
and the CCL2–CCR2 and CCL17/CCL22–CCR4 axes 
with regard to tumor migration and invasion in prostate 
cancer. We hypothesized that prostate cancer cells utilize 
the CCL2–CCR2 and CCL17/CCL22–CCR4 axes to 
metastasize through interactions between TAMs and 
prostate cancer cells.
We demonstrated the CCR2 and CCR4 gene and 
protein expressions in prostate cancer cells as well as in 
human prostate cancer tissues, which are novel findings 
for CCR4. Interestingly, CCL2 treatment resulted in 
significant increases in CCR2 and CCR4 protein levels 
in prostate cancer cells and promoted recruitment of 
monocytes into the tumor microenvironment, where they 
differentiated into TAMs. Inhibition of the CCL2–CCR2 
or CCL17/CCL22–CCR4 axis by specific antagonists 
of CCR2 or CCR4 clearly showed suppression of the 
migration ability of prostate cancer cells. Because the 
TMA analysis showed that the staining intensity of CCR4 
correlated with prostate cancer progression, while that of 
CCR2 did not, despite the fact that their intensities were 
correlated with each other, CCR4 may be a more powerful 
driver of prostate cancer migration and invasion than 
CCR2. The fact that phosphorylation of Akt proteins was 
more effectively inhibited by the CCR4 antagonist than by 
the CCR2 antagonist also indicates the efficiency of CCR4 
in prostate cancer migration and invasion. Akt activation 
is controlled by phosphorylation of the two key residues 
threonine 308 (Thr308) and serine 473 (Ser473) [22], 
and their phosphorylation promotes prostate cancer cell 
growth, proliferation, motility, and survival [23–25]. Our 
results indicated that the CCL22–CCR4 axis controlled 
phosphorylation of Ser473. It has been previously 
demonstrated that CCL2 promotes prostate cancer cell 
proliferation, migration, and survival via Akt-activation-
dependent mechanisms [26–28]. These results indicate 
that the CCL22–CCR4 axis is a better potential target than 
the CCL2–CCR2 axis for the future treatment of patients 
with prostate cancer (Figure 7).
Furthermore, the CCL22–CCR4 axis may be a novel 
biomarker for prostate cancer. The limitations of using a 
prostate-specific antigen alone as a biomarker for prostate 
cancer have been reported, and the necessity of more 
specific and effective biomarkers has been suggested [29, 
30]. Previously, we reported that the serum CCL2 level 
in patients with prostate cancer was clearly predictive of 
the time taken by the tumor to become castration resistant 
and of overall and prostate cancer-specific survivals [31]. 
However, additional clinical evidence is needed to show 
the superiority of the CCL22–CCR4 axis over the CCL2–
CCR2 axis as a prostate cancer biomarker.
MATERIALS AND METHODS
Reagents and antibodies
Recombinant human CCL17 and CCL22 were 
purchased from R&D Systems (Minneapolis, MN). 
Recombinant human CCL2 was obtained from BioLegend 
(San Diego, CA). Antibodies used in western blotting, 
IHC, immunocytochemistry, and flow cytometry were as 
follows: rabbit anti-human CCR2 antibody (ab21667), 
rabbit anti-human CCR4 antibody (ab83250), goat 
anti-human CCR4 antibody (ab1669), rabbit anti-goat 
immunoglobulin (Ig)G H&L (fluorescein isothiocyanate; 
FITC) antibody (6737), goat anti-rabbit IgG H&L 
(FITC) antibody (6717), anti-mannose receptor antibody 
(ab64693), and anti-CCR7 antibody (ab103404) obtained 
from Abcam (Cambridge, MA); anti-Akt antibody 
(9272), anti-phospho-Akt (Thr308) antibody (9275), anti-
phospho-Akt (Ser473) antibody (9271), and anti-rabbit 
IgG HRP-linked antibody (7074) obtained from Cell 
Signaling Technology (Danvers, MA); and anti-GAPDH 
antibody (NB300-221) obtained from Novus Biologicals 
(Littleton, CO). The antagonists used in the neutralizing 
assay were a selective CCR2 antagonist (ab120812) 
obtained from Abcam and a CCR4 antagonist (SC-
221406) obtained from Santa Cruz Biotechnology (Dallas, 
TX). The Akt inhibitor AZD5363 (S8019) was obtained 
from Selleckchem (Houston, TX).
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Cell culture
The human prostate cancer cell lines PC-3, DU145, 
and LNCaP were purchased from American Type Culture 
Collection (Manassas, VA). The human monocytoid cell 
lines U937 and THP-1 were purchased from HPA Culture 
Collections and Public Health England (Salisbury, UK). 
Prostate cancer cells were maintained in a humidified 
atmosphere of 5% CO2 at 37°C in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 5% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(Thermo Fisher Scientific, Waltham, MA). U937 and 
THP-1 cells were maintained in a humidified atmosphere 
of 5% CO2 at 37°C in RPMI 1640 medium supplemented 
with 10% FBS and 1% penicillin/streptomycin. An 
androgen-independent LNCaP cell line (LNCaP-SF) was 
established in our laboratory after long-term subculture of 
the parental LNCaP cells in Dulbecco's modified Eagle's 
medium supplemented with 5% charcoal-stripped FBS 
(CCS) and 1% penicillin/streptomycin.
Macrophage differentiation
M2-polarized U937 macrophages were generated as 
shown below. First, 20 ml of U937 cells (2.5 × 105 cells/
ml) were treated with 2 μl of PMA (100 ng/ml) and were 
then seeded into 6-well plates. Cells were incubated for 
24 h in a humidified atmosphere of 5% CO2 at 37°C to 
Figure 7: Schematic illustration of the spiral effects of the CCL2–CCR2 and CCL22–CCR4 axes through interactions 
between tumor-associated macrophages (TAMs) and prostate cancer cells. Infiltrated macrophages become M2-type cells 
(TAMs) through stimulation with prostate cancer cells. The interactions between TAMs and prostate cancer cells induce CCL2 in prostate 
cancer cells and affect the TAMs and prostate cancer cells in an autocrine manner. CCL2 upregulates its receptor, and through acceleration 
of the CCL2–CCR2 signal, CCL22 and CCR4 are upregulated. Subsequently, the CCL22–CCR4 axis activates Akt, which results in 
prostate cancer migration and invasion.
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differentiate into macrophages and then washed three 
times with PBS to remove PMA. Subsequently, the cells 
were exposed to CM of prostate cancer cells for 4 days.
Co-culture assay
The co-culture experiments were performed using 
transwell inserts in 6-well plates (cell culture inserts with 
1.0-μm pore sizes for 6-well plates; Greiner Bio-One, 
Monroe, NC). Briefly, PC-3, DU145, LNCaP, and LNCaP-
SF cells (1.0 × 105 cells) in the appropriate medium 
were placed into the upper compartment, and the lower 
compartment was filled with RPMI-1640 containing 5% 
FBS or 5% CCS. Cells were allowed to attach for 4 h, and 
then, U937 cells (2.0 × 105 cells) or M2-polarized U937 
macrophages were added to the lower compartment and 
co-cultured for 24 or 48 h.
RT-PCR analysis
Total RNA was isolated from the cultured cells 
using the RNeasy Mini Kit (Qiagen, Germantown, MD), 
following the manufacturer’s instructions. The RNA 
concentrations of the cell lines were measured using a 
NanoDrop spectrophotometer (Thermo Fisher Scientific). 
First-strand cDNA was prepared from an RNA template 
(500 ng) using the iScript cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA). Reverse transcription was performed at 
25°C for 5 min, 42°C for 30 min, and then 85°C for 5 
min. PCR amplification for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (98°C for 10 s, 60°C for 30 
s, 72°C for 60 s, 26 cycles), CCR2, and CCR4 (98°C 
for 10 s, 60°C for 30 s, 72°C for 60 s, 35 cycles) was 
performed using template cDNA and the TaKaRa Ex Taq 
Hot Start Version PCR kit (Takara Bio, Kusatsu, Japan). 
PCR products were electrophoresed on 1.5% agarose gels 
and stained with ethidium bromide. The sequences of the 
primers are shown in Supplementary Table S2.
Western blot analysis
Cell lysates were prepared with M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific). The 
soluble lysate (30 μg) was mixed with LDS sample buffer 
and sample reducing agent and was resolved with sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. The 
proteins were transferred to nitrocellulose membranes. 
The membranes were blocked with 1% gelatin in 0.05% 
Tween in Tris-buffered saline for 1 h at room temperature 
(RT) and then incubated overnight at 4°C with primary 
antibodies as indicated. CCR2, CCR4, Akt, and phospho-
Akt (Ser473) were detected using antibodies as described 
by the manufacturer. Membranes were washed three 
times before incubation with HRP-conjugated anti-rabbit 
secondary antibodies for 1 h at RT. Protein loading was 
determined with an anti-GAPDH antibody to detect 
levels of GAPDH. Protein bands were detected using 
SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Fisher Scientific). For analyses of upregulation 
of CCR4 and CCR2 in prostate cancer cells, the cells were 
seeded in 6-well plates and allowed to reach 60%–70% 
confluence, followed by incubation with recombinant 
human CCL2, CCL17, and CCL22 (30 ng/ml) for 24 h.
Immunocytochemical staining
The prostate cancer cells (1.0 × 105 cells/well) were 
seeded into 6-well plates and cultured until they reached 
60%–70% confluence. The cells were washed with PBS 
and fixed in 4% paraformaldehyde in PBS for 15 min 
at RT, and they were then washed three times with cold 
PBS before permeabilization with 0.25% Triton X-100 
in PBS for 15 min at RT. The cells were washed three 
times with PBS and blocked with 1% bovine serum 
albumin (BSA) in polybutylene succinate-co-butylene 
terephthalate at RT for 30 min, and they were then 
incubated with a primary antibody overnight at 4°C, as 
described by the manufacturer. CCR2 and CCR4 were 
detected by incubating the cells for 1 h with a secondary 
antibody conjugated with FITC (1:1000). The cells were 
counterstained with 4', 6-diamidino-2-phenylindole 
(Sigma-Aldrich, St. Louis, MO). Images were taken using 
Olympus FSX100 (Olympus, Tokyo, Japan).
Tissue microarray (TMA) analysis
A human prostate cancer TMA (PR 956a) was 
purchased from US Biomax (Rockville, MD). A TMA 
plate contains tissue samples from 8 patients with normal 
prostates and 36 patients with prostate cancer, and one or 
two spotted tissues of each patient are placed on the array. 
IHC staining was performed using the EnVision Detection 
System Peroxidase/DAB+ kit (K5007) according to the 
manufacturer’s protocol (Dako, Glostrup, Denmark) and 
the method described by Shin et al. [32]. Tissue specimens 
were stained with rabbit polyclonal antibody against CCR2 
and goat polyclonal antibody against CCR4. Microwave 
antigen retrieval was performed in Dako Target Retrieval 
Solution for 10 min. The arrays were analyzed by a 
blinded pathologist, and the intensities of the stained 
epithelial cells were recorded. Staining intensity was 
scored on a scale from – to +++ (–, negative; +, weak; ++, 
moderate; +++, strong intensity staining).
Wound-healing assay
LNCaP cells (1.0 × 106 cells/well) were seeded 
into 6-well plates. After reaching full confluence, the 
monolayer of cells was scratched with a 100-μl sterile 
pipette tip to make a vertical wound. To avoid the 
influence of the cell growth rate on wound healing, the 
tumor cell culture medium was changed from RPMI 
1640 medium supplemented with 5% FBS to RPMI 1640 
medium supplemented with 0.2% FBS and 0.2% BSA 
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or different concentrations of CCL2, CCL17, or CCL22. 
Phase-contrast images were taken of each sample at 0 
and 24 h with a 10× objective using Olympus FSX100. 
Migration activity was expressed by the transferred 
distance method measured using ImageJ (National 
Institutes of Health, Bethesda, MD) and calculated by 
subtraction of the distances at 0 h and 24 h. Three separate 
visual fields were measured in each experiment. Statistical 
analysis was performed using Student’s t-test. A p-value < 
0.05 was considered statistically significant.
Cell migration and invasion assay
The migration assay was performed using transwell 
inserts placed in a 24-well plate (cell culture inserts for 
24-well multiwell plates with 8.0-μm pore sizes; Greiner 
Bio-One). For the invasion assay, the transwell inserts 
were coated with 100 μl of 1:5 diluted Matrigel® (Corning, 
Corning, NY) in an atmosphere of 5% CO2 at 37°C for 5 h, 
and then, serum-free medium was added to the interior of 
the bottom compartment and to the upper compartment of 
the inserts and allowed to hydrate in an atmosphere of 5% 
CO2 at 37°C for 2 h. Prostate cancer cells (PC-3, DU145) 
were grown to 80% confluence in an appropriate medium. 
The cells were synchronized by starvation in serum-
free RPMI 1640 containing 0.5% BSA in a humidified 
atmosphere of 5% CO2 at 37°C for 16 h. Approximately 
2.5 × 104 cells in 200 μl of RPMI-1640 culture media 
supplemented with 0.1% FBS were placed in the upper 
compartment, and the lower compartment was filled with 
600 μl of RPMI-1640 containing 2% FBS. The cells were 
allowed to attach for 4 h, and then, the lower compartment 
was changed to 600 μl of RPMI-1640 containing 2% 
FBS with or without different concentrations of CCL2, 
CCL17, CCL22, and/or CM of U937 or M2-polarized 
U937 macrophages. The cancer cell invasion assay was 
cultured with or without 5.0 × 104 M2-polarized U937 
macrophages added to the lower compartment. The cells 
were incubated at 37°C in an atmosphere of 5% CO2 for 
20 h and fixed in 4% paraformaldehyde in PBS for 10 min. 
The cells on the upper surface of the filter were removed 
carefully with a cotton swab. The cells on the lower side 
of the filter were stained with 0.1% crystal violet for 15 
min, and the stained filters were photographed. The crystal 
violet dye retained on the filters was extracted into 33% 
acetic acid. Cell migration was measured by reading the 
absorbance at 590 nm and was corrected at 450 nm on a 
microplate reader. Statistical analysis was performed using 
Student’s t-test.
For the CCR2 and CCR4 neutralizing experiments, 
cancer cells were incubated with CCR2 or CCR4 
antagonist at a concentration ranging from 10 μg/ml to 
20 μg/ml in RPMI-1640 culture media supplemented with 
0.1% FBS at RT for 30 min and then seeded into the upper 
compartment. The lower compartment was filled with 
600 μl of RPMI-1640 containing 2% FBS with or without 
different concentrations of CCL2, CCL17, CCL22, and/
or CM from U937 or M2-polarized U937 macrophages. 
Cells were incubated in 5% CO2 at 37°C for 24 h (PC-3 
and DU145) or 48 h (LNCaP).
Human cytokine antibody array
CM was collected from PC-3 cells (control), 
PC-3 cells treated with CCL2 for 24 h, and PC-3 cells 
co-cultured with monocyte cell lines, THP-1, and U937 
cells. Cytokine levels were determined using a Human 
Cytokine Array kit (ARY017, R&D systems) according to 
the manufacturer’s instructions.
Enzyme-linked immunosorbent assay (ELISA) 
assay
Human CCL2 secretion was measured in serum-
free CM from PC-3, DU145, LNCaP, LNCaP-SF, and 
co-cultured media with U937 or macrophages using 
a Quantikine human ELISA kit purchased from R&D 
systems, according to the manufacturer’s instructions. 
Absorbance was measured at 450 nm and was corrected at 
540 nm on a microplate reader. Total protein concentrations 
of the CM were calculated using CurveExpert 1.4. 
(CurveExpert and GraphExpert Software, Madison, AL). 
Statistical analysis was performed using Student’s t-test. 
A p-value < 0.05 was considered statistically significant.
Conditioned medium (CM)
For preparing the prostate cancer cell CM, 1.0 × 
106 prostate cancer cells were seeded into 6-well culture 
plates and allowed to adhere overnight. On the next day, 
the medium was aspirated and 2 ml of medium containing 
1% FBS was added, and the supernatant was collected 48 
h later. The supernatant was centrifuged at 1800 rpm for 
10 min and was collected as CM.
CONCLUSION
To our knowledge, this is the first study to show 
that CCR4 was expressed in prostate cancer cell lines and 
human prostate cancer tissues and that the CCL22–CCR4 
axis contributed to prostate cancer migration and invasion. 
The CCL22–CCR4 axis, which is activated by TAMs, may 
be a novel therapeutic target and a potential biomarker for 
prostate cancer.
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